4.5 Article

Needle type and the risk of post-lumbar puncture headache in the outpatient neurology clinic

期刊

JOURNAL OF THE NEUROLOGICAL SCIENCES
卷 306, 期 1-2, 页码 24-28

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jns.2011.04.004

关键词

Lumbar puncture; Post-lumbar puncture headache; Needle type; Neurology outpatient clinic

向作者/读者索取更多资源

Objective: Post-lumbar puncture headaches (PLPHs) are a common complication of diagnostic lumbar punctures (LPs) caused by a persistent leak of spinal fluid from the dural puncture site. We conducted a prospective study to determine risk factors associated with PLPHs in the neurology outpatient setting. Methods: Clinical information from all diagnostic LPs performed at the Johns Hopkins Lumbar Puncture Clinic between September 2008 and June 2009 was reviewed. As standard of care, each patient was contacted by telephone by the attending physician within 2-5 days of having an LP to ascertain health status and the presence of PLPH. We performed multiple logistic regression analysis to evaluate the association between PLPH and needle type (traditional Quincke cutting needle 20 and 22 gauge, 20Q and 22Q and Sprotte non-traumatic gauge 22 needle, 22S) adjusting for important variables such as traumatic LPs, number of attempts, positioning and volume of CSF drawn. Results: The prevalence of PLPH was 32% with the popular gauge 20Q and 22Q needles compared to 19% with the 22S non-traumatic needle. Compared to the 20Q needle, the non-traumatic 22S needle was associated with 69% decreased odds of PLPH (adjusted OR: 031,95% CI 0.12-0.82). In subset analysis, the odds of PLPH increased 4-fold when the 22Q needle was used compared to the 22S needle (adjusted OR = 3.99, 95% CI 132-12.0). Conclusions: Our outpatient findings support the American Academy of Neurology recommendations to use smaller non-traumatic needles to reduce the risk of PLPH. (C) 2011 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Editorial Material Clinical Neurology

Expanding the spectrum of MOG antibody disease

Michael Levy

MULTIPLE SCLEROSIS JOURNAL (2020)

Article Clinical Neurology

Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders

Itay Lotan, Robert W. Charlson, Lana Zhovtis Ryerson, Michael Levy, Ilya Kister

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)

Editorial Material Clinical Neurology

Rethinking high-risk groups in COVID-19

Anastasia Vishnevetsky, Michael Levy

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)

Article Clinical Neurology

Paroxysmal symptoms in neuromyelitis optica spectrum disorder: Results from an online patient survey

Itay Lotan, Tamar Bacon, Ilya Kister, Michael Levy

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)

Article Clinical Neurology

Evidence of subclinical quantitative retinal layer abnormalities in AQP4-IgG seropositive NMOSD

Angeliki G. Filippatou, Eleni S. Vasileiou, Yufan He, Kathryn C. Fitzgerald, Grigorios Kalaitzidis, Jeffrey Lambe, Maureen A. Mealy, Michael Levy, Yihao Liu, Jerry L. Prince, Ellen M. Mowry, Shiv Saidha, Peter A. Calabresi, Elias S. Sotirchos

Summary: This study compared retinal layer thicknesses between AQP4-IgG+ NMOSD eyes without a history of ON and healthy controls using OCT, finding evidence of subclinical retinal ganglion cell neuronal and axonal loss, as well as photoreceptor layer involvement in AQP4-nonON eyes. These results suggest that subclinical anterior visual pathway involvement may occur in AQP4-IgG+ NMOSD.

MULTIPLE SCLEROSIS JOURNAL (2021)

Article Clinical Neurology

Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD

Dean M. Wingerchuk, Kazuo Fujihara, Jacqueline Palace, Achim Berthele, Michael Levy, Ho Jin Kim, Ichiro Nakashima, Celia Oreja-Guevara, Kai-Chen Wang, Larisa Miller, Shulian Shang, Guido Sabatella, Marcus Yountz, Sean J. Pittock

Summary: This study demonstrates that the long-term safety profile of eculizumab in NMOSD is consistent with its established profile across other indications. Long-term treatment with eculizumab has shown sustained ability to reduce relapse risk in patients with AQP4-IgG+ NMOSD, with some patients also reducing or stopping background immunosuppressive therapy.

ANNALS OF NEUROLOGY (2021)

Review Clinical Neurology

Bright spotty lesions as an imaging marker for neuromyelitis optica spectrum disorder

Sara Salama, Michael Levy

Summary: It is important to diagnose NMOSD early to initiate long-term treatment and avoid potentially harmful treatments. Spinal imaging features such as LETM and BSLs can aid in diagnosis.

MULTIPLE SCLEROSIS JOURNAL (2022)

Article Clinical Neurology

Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension

Sean J. Pittock, Kazuo Fujihara, Jacqueline Palace, Achim Berthele, Ho Jin Kim, Celia Oreja-Guevara, Ichiro Nakashima, Michael Levy, Shulian Shang, Marcus Yountz, Larisa Miller, Roisin Armstrong, Dean M. Wingerchuk

Summary: Eculizumab monotherapy effectively prevents relapses in AQP4-IgG + NMOSD patients, relieving the burden of chronic immunosuppression.

MULTIPLE SCLEROSIS JOURNAL (2022)

Article Clinical Neurology

Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease

Paula Barreras, Eleni S. Vasileiou, Angeliki G. Filippatou, Kathryn C. Fitzgerald, Michael Levy, Carlos A. Pardo, Scott D. Newsome, Ellen M. Mowry, Peter A. Calabresi, Elias S. Sotirchos

Summary: Rituximab treatment reduces the annualized relapse rate in AQP4-IgG-seropositive NMOSD, especially when administered consistently without gaps in treatment or B-cell reconstitution. In MOGAD patients, although a decrease in relapses was observed after rituximab initiation, this effect appeared to be less pronounced compared to AQP4-IgG-seropositive NMOSD. Severe infections and hypogammaglobulinemia were seen in a significant number of patients, underscoring the importance of close monitoring for infectious complications.

NEUROLOGY (2022)

Review Biotechnology & Applied Microbiology

Transitioning immunotherapy in neuromyelitis optica spectrum disorder - when and how to switch

Anastasia Vishnevetsky, Tamara B. Kaplan, Michael Levy

Summary: This review focuses on the practical questions of managing and switching immunotherapies for NMOSD. It highlights the challenges faced and future research directions in this area.

EXPERT OPINION ON BIOLOGICAL THERAPY (2022)

Article Clinical Neurology

Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder

Sean J. Pittock, Michael Barnett, Jeffrey L. Bennett, Achim Berthele, Jerome de Seze, Michael Levy, Ichiro Nakashima, Celia Oreja-Guevara, Jacqueline Palace, Friedemann Paul, Carlo Pozzilli, Marcus Yountz, Kerstin Allen, Yasmin Mashhoon, Ho Jin Kim

Summary: The CHAMPION-NMOSD study evaluated the efficacy and safety of ravulizumab in adult patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. Ravulizumab, which has a longer half-life compared to eculizumab, significantly reduced relapse risk in these patients.

ANNALS OF NEUROLOGY (2023)

Article Clinical Neurology

Low mortality rate in a large cohort of myelin oligodendrocyte glycoprotein antibody disease (MOGAD)

Itay Lotan, Gabriela Romanow, Rebecca Salky, Negar Molazadeh, Anastasia Vishnevetsky, Monique Anderson, Phillipe-Antoine Bilodeau, Gary Cutter, Michael Levy

Summary: This study aimed to assess the mortality rate in patients with MOGAD and found a lower mortality rate compared to other neuroinflammatory diseases, similar to the age-adjusted mortality rates of the general population in the United States. Further studies are needed to confirm this observation.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2023)

Article Clinical Neurology

Hypogammaglobulinemia secondary to B-cell depleting therapies in neuroimmunology: Comparing management strategies

Hannah Kelly, Anastasia Vishnevetsky, Lori B. Chibnik, Michael Levy

Summary: This study compared strategies to manage secondary hypogammaglobulinemia in neuroimmunology patients, including reducing anti-CD20 dose and dosing frequency, IVIG/SCIG, anti-CD20 cessation, and DMT switches. The results suggest that IVIG/SCIG may yield the greatest recovery in IgG while also reducing infection frequency and severity. Stopping anti-CD20 therapy and/or switching DMTs can also increase IgG and lower infection risk.

MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL (2023)

Review Clinical Neurology

Autoimmune diseases and cancers overlapping with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): A systematic review

Negar Molazadeh, Gauruv Bose, Itay Lotan, Michael Levy

Summary: MOGAD shares similarities with AQP4-IgG + NMOSD in clinical presentations and treatment responses, but has less clear associations with autoimmune diseases and cancers compared to AQP4-IgG + NMOSD, suggesting routine screening for overlapping autoimmunity and neoplasms in MOGAD patients may not be necessary.

MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL (2022)

Review Medicine, General & Internal

Differential diagnosis of multiple sclerosis

Julien J. Cavanagh, Michael Levy

Summary: This review aims to help clinicians differentiate between multiple sclerosis and other similar conditions, highlighting the importance of carefully considering the differences between various diseases in diagnosis and treatment.

PRESSE MEDICALE (2021)

暂无数据